NORTHWELL HEALTH

INO-3107 induced new clonal T cells in blood, which traveled to papilloma and airway tissues, generating an inflammatory and anti-viral response, potentially reducing surgeries for RRP patients with HPV-6 and HPV-11.

Molecular testing and targeted therapy influence surgical treatment plans for non–small cell lung cancer (NSCLC). For early-stage NSCLC, reflex testing identifies mutations to guide neoadjuvant therapy. Advanced NSCLC patients undergo biopsy for molecular profiling to tailor frontline treatment. Asian women with adenocarcinoma often have actionable EGFR mutations, potentially qualifying for targeted postoperative therapy. In advanced cases where surgery is infeasible, tissue sampling guides therapeutic decisions based on molecular profiling.

Medical device innovations, including MMI's Symani surgical system and Asensus Surgical's AugmentOR Portal, are among Time's best inventions of 2024. Other notable devices include BiVacor's artificial heart, Dexcom's Stelo CGM, Onward Medical's ARC-EX spine stimulator, EarliTec's EarliPoint for autism diagnosis, Paragonix's Baroguard for lung preservation, DermaSensor's skin cancer detection device, Northwell Health's iNav and Double Neural Bypass, Masimo's W1 Medical watch, Apple's AirPods Pro 2 as hearing aids, Withings' BeamO home checkup device, ALZpath's pTau217 Alzheimer's test, Aspivix's Carevix for IUD pain management, Unify Medical's Amplio surgical visualization system, AstraZeneca's FluMist nasal vaccine, Nuvo's Invu remote pregnancy monitor, Daye's diagnostic tampon, Winx's UTI Test + Treat, PherDal's At-Home Insemination Kit, GyroGear's GyroGlove for tremor stabilization, Prenosis' Sepsis ImmunoScore, Guardant Health's Shield for cancer screening, and ArteraAI's Multimodal AI for prostate cancer treatment planning.

START Center for Cancer Research partners with Fundación Rioja Salud to expand early-phase cancer clinical trials in La Rioja, Spain, establishing a unit at San Pedro University Hospital to serve northern regions, potentially benefiting over 8.1 million people.

Bimekizumab, a dual interleukin-17A and 17F inhibitor, showed durability and consistency in treating moderate to severe HS over 96 weeks, significantly reducing draining tunnels and improving patient-reported outcomes. This could guide long-term treatment strategies and potentially allow for less frequent dosing while maintaining effective disease control.

The START Center for Cancer Research partners with Fundación Rioja Salud to establish an early-phase cancer clinical trial unit in La Rioja, Spain, expanding access to innovative cancer treatments.

Talia R. Kaden, MD, discussed cases of polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME), retinal vein occlusions (RVOs), and neovascular age-related macular degeneration (nAMD) treated with faricimab and aflibercept. Key points include the need for chronic therapy in PCV, the efficacy of faricimab in DME, the challenges in treating RVO, and the cautious approach to treatment interval extension in nAMD. Kaden also highlighted the potential of gene therapies and the Port Delivery System for resistant cases.

Matthew Lawrence Inra, MD, discusses the role of thoracic surgeons and multidisciplinary collaboration in early-stage lung cancer treatment at Lenox Hill Hospital and Northwell Health. He emphasizes the importance of early tumor tissue collection for biomarker testing, which guides personalized treatment decisions. Inra highlights the shift toward targeted therapy and immunotherapy based on molecular profiles, and the need to educate patients on the value of these personalized treatments.

Becker's honors healthcare CNOs for tackling nurse staffing shortages, managing budgets, and developing professional growth opportunities. CNOs oversee nursing departments, spearhead innovative patient care initiatives, and bring clinical expertise and executive leadership skills. The list is based on nominations and editorial research, with leaders presented in alphabetical order.